Cargando…
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse mye...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063869/ https://www.ncbi.nlm.nih.gov/pubmed/37008248 http://dx.doi.org/10.1177/11795735231167869 |
_version_ | 1785017784363646976 |
---|---|
author | Mirmosayyeb, Omid Ghaffary, Elham Moases Dehghan, Mohammad S. Ghoshouni, Hamed Bagherieh, Sara Barzegar, Mahdi Shaygannejad, Vahid |
author_facet | Mirmosayyeb, Omid Ghaffary, Elham Moases Dehghan, Mohammad S. Ghoshouni, Hamed Bagherieh, Sara Barzegar, Mahdi Shaygannejad, Vahid |
author_sort | Mirmosayyeb, Omid |
collection | PubMed |
description | BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse myelitis (ATM), and MOGAD, have been reported following the COVID-19 infection during the current COVID-19 pandemic. On the other hand, it has been suggested that patients with MOGAD may be at greater risk for infection (particularly in the current pandemic). OBJECTIVE: In this systematic review, we gathered separately 1) MOGAD cases following COVID-19 infection as well as 2) clinical course of patients with MOGAD infected with COVID-19 based on case reports/series. METHODS: 329 articles were collected from 4 databases. These articles were conducted from inception to March 1(st), 2022. RESULTS: Following the screening, exclusion criteria were followed and eventually, 22 studies were included. In 18 studies, a mean ± SD time interval of 18.6 ± 14.9 days was observed between infection with COVID-19 and the onset of MOGAD symptoms. Symptoms were partially or completely recovered in a mean of 67 days of follow-up. Among 4 studies on MOGAD patients, the hospitalization rate was 25%, and 15% of patients were hospitalized in the intensive care unit (ICU). CONCLUSION: Our systematic review demonstrated that following COVID-19 infection, there is a rare possibility of contracting MOGAD. Moreover, there is no clear consensus on the susceptibility of MOGAD patients to severe COVID-19. However, obtaining deterministic results requires studies with a larger sample size. |
format | Online Article Text |
id | pubmed-10063869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-100638692023-03-31 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review Mirmosayyeb, Omid Ghaffary, Elham Moases Dehghan, Mohammad S. Ghoshouni, Hamed Bagherieh, Sara Barzegar, Mahdi Shaygannejad, Vahid J Cent Nerv Syst Dis COVID-19 – Advances, Challenges and Observations BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse myelitis (ATM), and MOGAD, have been reported following the COVID-19 infection during the current COVID-19 pandemic. On the other hand, it has been suggested that patients with MOGAD may be at greater risk for infection (particularly in the current pandemic). OBJECTIVE: In this systematic review, we gathered separately 1) MOGAD cases following COVID-19 infection as well as 2) clinical course of patients with MOGAD infected with COVID-19 based on case reports/series. METHODS: 329 articles were collected from 4 databases. These articles were conducted from inception to March 1(st), 2022. RESULTS: Following the screening, exclusion criteria were followed and eventually, 22 studies were included. In 18 studies, a mean ± SD time interval of 18.6 ± 14.9 days was observed between infection with COVID-19 and the onset of MOGAD symptoms. Symptoms were partially or completely recovered in a mean of 67 days of follow-up. Among 4 studies on MOGAD patients, the hospitalization rate was 25%, and 15% of patients were hospitalized in the intensive care unit (ICU). CONCLUSION: Our systematic review demonstrated that following COVID-19 infection, there is a rare possibility of contracting MOGAD. Moreover, there is no clear consensus on the susceptibility of MOGAD patients to severe COVID-19. However, obtaining deterministic results requires studies with a larger sample size. SAGE Publications 2023-03-29 /pmc/articles/PMC10063869/ /pubmed/37008248 http://dx.doi.org/10.1177/11795735231167869 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | COVID-19 – Advances, Challenges and Observations Mirmosayyeb, Omid Ghaffary, Elham Moases Dehghan, Mohammad S. Ghoshouni, Hamed Bagherieh, Sara Barzegar, Mahdi Shaygannejad, Vahid Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review |
title | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review |
title_full | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review |
title_fullStr | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review |
title_full_unstemmed | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review |
title_short | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review |
title_sort | myelin oligodendrocyte glycoprotein antibody-associated disease and covid-19: a systematic review |
topic | COVID-19 – Advances, Challenges and Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063869/ https://www.ncbi.nlm.nih.gov/pubmed/37008248 http://dx.doi.org/10.1177/11795735231167869 |
work_keys_str_mv | AT mirmosayyebomid myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview AT ghaffaryelhammoases myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview AT dehghanmohammads myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview AT ghoshounihamed myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview AT bagheriehsara myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview AT barzegarmahdi myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview AT shaygannejadvahid myelinoligodendrocyteglycoproteinantibodyassociateddiseaseandcovid19asystematicreview |